Dowling & Yahnke’s Kyntra Bio KYNB Stock Holding History

Dowling & Yahnke’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-258	Closed	-$224K	–	372
2021 Q1	$224K	Hold	258	–	–	0.02%	316
2020 Q4	$239K	Hold	258	–	–	0.02%	300
2020 Q3	$265K	Buy	+258	New	+$278K	0.02%	279

Other funds holding KYNB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dowling & Yahnke's KYNB Position: Q2 2021 in Review

Dowling & Yahnke sold out of Kyntra Bio (KYNB) in Q2 2021, closing a stake of 258 shares — an estimated $224K sold.

Dowling & Yahnke first reported a position in KYNB in Q3 2020 and held it in 3 quarters. The position peaked at $265K in Q3 2020. 175 funds tracked by Wall St. Rank hold KYNB as of Q2 2021.

Dowling & Yahnke reported no remaining Kyntra Bio position as of Q2 2021 after selling out during the quarter.
Dowling & Yahnke sold 258 Kyntra Bio shares in Q2 2021, an estimated $224K.
Dowling & Yahnke first reported a position in Kyntra Bio in Q3 2020 and held it in 3 quarters.
Dowling & Yahnke's Kyntra Bio position peaked at $265K in Q3 2020.
175 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2021.

Based on Dowling & Yahnke's 13F filing for Q2 2021, filed 21 Jul 2021.